Praxis Precision Medicines Stock - Analyst consensus and trading snapshot
18.06.2026 - 19:31:06 | ad-hoc-news.de
Edited by ad hoc news Chart & Technicals Desk. Verified prior to publication on 06/18/2026, 17:20 UTC. Details in the imprint.
Praxis Precision Medicines (US74006W1036) is trading through a quiet news spell, with no fresh corporate or regulatory updates over the past day. On Thursday, investor attention therefore centers on analyst consensus, recent quote levels and the stock’s volatility profile on Nasdaq.
All news and data on Praxis Precision Medicines
Key figures, regulatory filings and historical news on Praxis Precision Medicines stock are available in bundled form via the ad hoc news topic page and the company’s investor-relations site.
What recent trading shows
Praxis Precision Medicines shares most recently changed hands around the upper-$270s range on Nasdaq, with MarketBeat citing a fair value quote of about $278 shortly after midday Eastern on Thursday. Intraday, the name showed a low single-digit percentage move, consistent with its typical volatility.
Discussion forums such as Stocktwits also reflected active intraday interest, with users referencing the stock near the same price band and noting the day’s percentage change in the mid-single-digit range. For retail traders, this positions the stock clearly at the speculative end of the biotech universe.
Analyst views and consensus
On the analyst side, major houses followed the stock more actively earlier in the year around pipeline milestones, but there have been no prominent rating or price-target changes published over the last 24 hours according to common aggregators. As a result, investors currently rely on the standing mix of Buy and Hold recommendations set in previous months.
Consensus models in these databases continue to tie the stock’s fundamental outlook largely to execution on its central nervous system portfolio, rather than near-term earnings metrics. For a pre-commercial biotech with a focused pipeline, this pattern is typical, as valuation is primarily driven by trial progress and regulatory events.
The product behind the stock
Praxis Precision Medicines develops therapies for central nervous system disorders, including movement and psychiatric conditions, with several candidates in clinical and preclinical stages. The company’s programs aim to modulate neuronal circuits, targeting diseases such as essential tremor, depression and other neurologic indications.
Where the stock trades today
The shares of Praxis Precision Medicines (US74006W1036) trade on Nasdaq at approximately $278.70 as of 06/18/2026, 12:59 Eastern Time.
Praxis Precision Medicines at a glance
- Company: Praxis Precision Medicines Inc.
- ISIN: US74006W1036
- WKN: A2QK2L
- Ticker: PRAX
- Venue: Nasdaq
- Price (as of 06/18/2026, 12:59 Eastern Time): 278.70 USD
- Market cap: 11.9 billion USD (as of 06/18/2026)
- Sector / Industry: Health Care / Biotechnology
- Index membership: not a member of the S&P 500 or Nasdaq-100
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
